These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 16215305

  • 1. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
    Mottet N, Lucas C, Sene E, Avances C, Maubach L, Wolff JM.
    Urol Int; 2005; 75(3):204-8. PubMed ID: 16215305
    [Abstract] [Full Text] [Related]

  • 2. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 3. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM, Rose AL, Higano C.
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [Abstract] [Full Text] [Related]

  • 4. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM, TAP22 Investigators Group.
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [Abstract] [Full Text] [Related]

  • 5. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
    Ng E, Woo HH, Turner S, Leong E, Jackson M, Spry N.
    J Urol; 2012 Jun; 187(6):2162-6. PubMed ID: 22503022
    [Abstract] [Full Text] [Related]

  • 6. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.
    Spry NA, Kristjanson L, Hooton B, Hayden L, Neerhut G, Gurney H, Corica T, Korbel E, Weinstein S, McCaul K.
    Eur J Cancer; 2006 May; 42(8):1083-92. PubMed ID: 16632343
    [Abstract] [Full Text] [Related]

  • 7. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ.
    Eur Urol; 1999 May; 35 Suppl 1():32-6. PubMed ID: 10081701
    [Abstract] [Full Text] [Related]

  • 8. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R, Renneberg H, Lübben G, Kienle E, Tunn UW.
    Eur Urol; 1999 May; 35 Suppl 1():27-31. PubMed ID: 10081700
    [Abstract] [Full Text] [Related]

  • 9. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
    Malone S, Perry G, Segal R, Dahrouge S, Crook J.
    BJU Int; 2005 Sep; 96(4):514-20. PubMed ID: 16104902
    [Abstract] [Full Text] [Related]

  • 10. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.
    Tunn UW, Canepa G, Kochanowsky A, Kienle E.
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):296-302. PubMed ID: 22733160
    [Abstract] [Full Text] [Related]

  • 11. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE.
    Eur Urol; 1997 Sep; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [Abstract] [Full Text] [Related]

  • 12. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [Abstract] [Full Text] [Related]

  • 13. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL, FinnProstate Group.
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [Abstract] [Full Text] [Related]

  • 14. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I.
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [Abstract] [Full Text] [Related]

  • 15. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
    Boccon-Gibod L, Albers P, Morote J, van Poppel H, de la Rosette J, Villers A, Malmberg A, Neijber A, Montorsi F.
    Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
    [Abstract] [Full Text] [Related]

  • 16. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [Abstract] [Full Text] [Related]

  • 17. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 18. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 01; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 19. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N, Klotz L, Crook J, Goldenberg SL.
    Cancer; 2007 Mar 01; 109(5):858-67. PubMed ID: 17265527
    [Abstract] [Full Text] [Related]

  • 20. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar 01; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.